HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
11- deoxy- 16- phenoxy- 17,18,19,20- tetranorprostaglandin E1
an EP3 agonist; RN refers to (1R-(1alpha,2beta(1E,3R*)))-isomer
Also Known As:
11-deoxy-16-phenoxy-17,18,19,20-tetranor-PGE1; DPT-prostaglandin E1; M&B 28,767; M&B 28767; M&B-28767; M&B28767; MB-28767; Cyclopentaneheptanoic acid, 2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxo-, (1R-(1alpha,2beta(1E,3R*)))-
Networked:
3
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1: 3
Monounsaturated Fatty Acids: 676
Alprostadil: 3107
11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1: 3
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
Prostaglandins E: 2673
Alprostadil: 3107
11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1: 3
Related Diseases
1.
Infarction (Infarctions)
02/01/1999 - "
3. M&B 28767 (0.5 microg kg(-1) min(-1), i.v., n=7) or GR 63799X (3 microg kg(-1) min(-1), i.v., n=7) caused significant reductions in infarct size from 60+/-3% (25 min ischaemia and 2 h reperfusion; saline-control, n=8) to 39+/-6 and 38+/-4% of the area at risk, without causing a significant fall in blood pressure.
"
02/01/1999 - "
1. This study investigates the effects of two agonists of the prostanoid EP3-receptor (M&B 28767 and GR 63799X) on the infarct size caused by regional myocardial ischaemia and reperfusion in the anaesthetized rat.
"
02/01/1999 - "
Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat.
"
02/01/1999 - "
The reduction in infarct size afforded by M&B 28767 was also abolished by glibenclamide and the protein kinase C (PKC) inhibitors staurosporine and chelerythrine.
"
2.
Ulcer
12/17/1984 - "
M&B 28,767: a potent anti-secretory and anti-ulcer PG analogue.
"
3.
Myocardial Infarction
02/01/1999 - "
4. Thus, M&B 28767 and GR 63799X reduce myocardial infarct size in the rat by a mechanism(s) which involves the activation of PKC and the opening of ATP-sensitive potassium channels.
"
4.
Hyperalgesia
07/01/1997 - "
The microinjection of M&B28767 at 0.5 fg into the other parts of preoptic hypothalamus (the lateral part of the preoptic area and the median preoptic nucleus) and the diagonal band of Broca (DBB) produced hyperalgesia similar to the intraMPO-induced hyperalgesia in terms of magnitude and time course.
"
5.
Constipation
12/17/1984 - "
In another test, M&B 28,767 (0.5-5.0 mg/kg) and DMPG (10-40 micrograms/kg) overcame morphine-induced constipation in a dose-related manner, the respective ED50s being 0.9-1.4 mg/kg and 20-40 micrograms/kg. Thus, M&B 28,767 had a better profile of activity than DMPG as an antisecretory and antiulcer agent.
"
Related Drugs and Biologics
1.
Prostaglandins
2.
GR 63799X
3.
KATP Channels
4.
Staurosporine
5.
Protein Kinase C
6.
Morphine (MS Contin)
7.
Glyburide (Glibenclamide)
8.
chelerythrine
9.
dimyristoylphosphatidylglycerol (DMPG)